Upstream Bio (UPB) Expected to Announce Earnings on Thursday

Upstream Bio (NASDAQ:UPB) is anticipated to announce its earnings results before the market opens on Thursday, February 27th. Analysts expect Upstream Bio to post earnings of ($0.56) per share for the quarter.

Upstream Bio Stock Performance

Shares of UPB opened at $8.22 on Tuesday. Upstream Bio has a 1 year low of $6.65 and a 1 year high of $29.46. The business’s 50 day moving average price is $12.38.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Piper Sandler started coverage on shares of Upstream Bio in a research report on Tuesday, November 5th. They set an “overweight” rating and a $75.00 price objective for the company. TD Cowen began coverage on shares of Upstream Bio in a research report on Tuesday, November 5th. They set a “buy” rating on the stock. William Blair assumed coverage on shares of Upstream Bio in a report on Tuesday, November 5th. They issued an “outperform” rating for the company. Finally, JPMorgan Chase & Co. initiated coverage on shares of Upstream Bio in a research note on Tuesday, November 5th. They set an “overweight” rating and a $38.00 price target for the company.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.